Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5883005 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 7 Pages |
Abstract
Dasatinib and nilotinib were more effective than imatinib as first-line therapy for CML in a community setting, as observed in descriptive and univariate analyses. The frequency of cytogenetic and molecular monitoring was lower than that recommended by current guidelines, including patients with no molecular or cytogenetic assessments during the 18-month follow-up. Therefore, MSH/USON is working toward improving compliance with response monitoring guidelines.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Nicholas J. Di Bella, Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Zachary Cain, Tony Okoro, Bjorn Bolinder, Debra Patt, Elias J. Jabbour,